Synairgen（SYGG.F）株式概要Synairgen plcは呼吸器疾患の治療薬を発見・開発している。 詳細SYGG.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析株式の流動性は非常に低い 収益が 100 万ドル未満 ( £0 )意味のある時価総額がありません ( $110K )最新の財務報告は6か月以上前のものである すべてのリスクチェックを見るSYGG.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0001該当なし内在価値ディスカウントEst. Revenue$PastFuture-49m5m2016201920222025202620282031Revenue UK£1.0Earnings UK£0.2AdvancedSet Fair ValueView all narrativesSynairgen plc 競合他社OnconetixSymbol: NasdaqCM:ONCOMarket cap: US$85.9kVincerx PharmaSymbol: OTCPK:VINCMarket cap: US$67.3kBeroni GroupSymbol: OTCPK:BNIG.FMarket cap: US$217.5kLipella PharmaceuticalsSymbol: OTCPK:LIPOMarket cap: US$462.1k価格と性能株価の高値、安値、推移の概要Synairgen過去の株価現在の株価US$0.000152週高値US$0.000452週安値US$0.000001ベータ4.331ヶ月の変化0%3ヶ月変化n/a1年変化0%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Feb 27Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical StudySynairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it.お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdomお知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.最新情報をもっと見るRecent updatesお知らせ • Feb 27Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical StudySynairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it.お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdomお知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.お知らせ • Oct 05Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical OfficerSynairgen plc announces the appointment of Dr. Marcin Mankowski as Chief Medical Officer (CMO), effective immediately. Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018. Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom株主還元SYGG.FUS BiotechsUS 市場7D0%3.1%1.2%1Y0%34.6%28.7%株主還元を見る業界別リターン: SYGG.F過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: SYGG.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is SYGG.F's price volatile compared to industry and market?SYGG.F volatilitySYGG.F Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: SYGG.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSYGG.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト200434Joseph Colliverwww.synairgen.comSynairgen plcは呼吸器疾患の治療薬の発見と開発を行っている。また、コロナウイルスを含むウイルスと闘うために免疫系を調整する天然由来のタンパク質である吸入インターフェロンベータIFN-ßを開発している。シナールジェン社は2004年に設立され、英国サウサンプトンに本社を置いている。もっと見るSynairgen plc 基礎のまとめSynairgen の収益と売上を時価総額と比較するとどうか。SYGG.F 基礎統計学時価総額US$110.27k収益（TTM）-US$9.20m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率SYGG.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SYGG.F 損益計算書（TTM）収益UK£0売上原価UK£0売上総利益UK£0その他の費用UK£6.81m収益-UK£6.81m直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.0062グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%SYGG.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 13:21終値2026/03/09 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synairgen plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMark BrewerCavendish
お知らせ • Feb 27Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical StudySynairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it.
お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.
お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdom
お知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.
お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.
お知らせ • Feb 27Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical StudySynairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it.
お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.
お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdom
お知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.
お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.
お知らせ • Oct 05Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical OfficerSynairgen plc announces the appointment of Dr. Marcin Mankowski as Chief Medical Officer (CMO), effective immediately. Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018. Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.
お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom
